Sol-Gel Technologies Net Profit Margin 2016-2024 | SLGL
Sol-Gel Technologies net profit margin from 2016 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Sol-Gel Technologies Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2024-09-30 |
$0.01B |
$-0.01B |
-90.00% |
| 2024-06-30 |
$0.01B |
$-0.02B |
-300.00% |
| 2024-03-31 |
$0.00B |
$-0.02B |
-2300.00% |
| 2023-12-31 |
$0.00B |
$-0.03B |
-2800.00% |
| 2023-09-30 |
$0.00B |
$-0.03B |
-2900.00% |
| 2023-06-30 |
$0.00B |
$-0.03B |
-2600.00% |
| 2023-03-31 |
$0.00B |
$-0.02B |
-500.00% |
| 2022-12-31 |
$0.00B |
$-0.02B |
-375.00% |
| 2022-09-30 |
$0.03B |
$0.01B |
20.00% |
| 2022-06-30 |
$0.03B |
$0.01B |
26.47% |
| 2022-03-31 |
$0.03B |
$0.00B |
3.23% |
| 2021-12-31 |
$0.03B |
$0.00B |
9.38% |
| 2021-09-30 |
$0.01B |
$-0.02B |
-130.77% |
| 2021-06-30 |
$0.01B |
$-0.03B |
-450.00% |
| 2021-03-31 |
$0.01B |
$-0.03B |
-433.33% |
| 2020-12-31 |
$0.01B |
$-0.03B |
-362.50% |
| 2020-09-30 |
$0.01B |
$-0.03B |
-300.00% |
| 2020-06-30 |
$0.01B |
$-0.03B |
-215.38% |
| 2020-03-31 |
$0.02B |
$-0.03B |
-130.00% |
| 2019-12-31 |
$0.02B |
$-0.03B |
-108.70% |
| 2019-09-30 |
$0.02B |
$-0.03B |
-157.89% |
| 2019-06-30 |
$0.01B |
$-0.03B |
-221.43% |
| 2019-03-31 |
$0.01B |
$-0.03B |
-550.00% |
| 2018-12-31 |
$0.00B |
$-0.03B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.012B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
